机构：[1]Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China,[2]State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China,[3]Institute of Respiratory Disease, First Hospital of China Medical University, Shenyang, China,[4]Beijing Novartis Pharma Co. Ltd., Beijing, China,[5]China Novartis Institutes for Biomedical Research Co., Ltd., Shanghai, China,[6]Novartis Pharma AG, Basel, Switzerland,[7]Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
第一作者机构：[1]Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China,
推荐引用方式(GB/T 7714)：
Wang C.,Li J.,Kang J.,et al.Clinical Efficacy of Omalizumab, as Measured by Patient-Reported Outcomes, in Chinese Patients with Moderate or Severe Allergic Asthma[J].AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.2018,197:
APA：
Wang, C.,Li, J.,Kang, J.,Yang, J.,Lin, Z....&Zhong, N..(2018).Clinical Efficacy of Omalizumab, as Measured by Patient-Reported Outcomes, in Chinese Patients with Moderate or Severe Allergic Asthma.AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,197,
MLA：
Wang, C.,et al."Clinical Efficacy of Omalizumab, as Measured by Patient-Reported Outcomes, in Chinese Patients with Moderate or Severe Allergic Asthma".AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 197.(2018)
医学